/ /

  • linkedin
  • Increase Font
  • Sharebar

    MICS & MIGS: combined surgery with microstent devices



    In patients with mild–moderate glaucoma with an IOP that has been unable to be controlled by medications or who have poor medication compliance, MIGS appears to be a viable option. Clinical trials have shown there to be a significant decrease in IOP over periods of up to 24 months, along with a significant decrease in medication usage. The procedure has maintained a high safety profile with minimal adverse effects. There are a few FDA-approved devices, such as iStent, and multiple new devices pending, such as XEN Gel Stent. MIGS can provide a method of treatment for glaucoma patients that decreases reliance on medications without the safety risks of more invasive procedures.

    The combination of MICS and MIGS by implanting a microstent can offer an effective surgical treatment of POAG because the reduction of IOP caused by cataract surgery alone may not be sufficient to reduce a patient’s need for glaucoma therapies.  


    1. Quigley HA, Broman AT. Br. J. Ophthalmol. 2006; 90(3): 262-267.

    2. Randy Craven E, et al., J. Cataract. Refract. Surg. 2012; 38(8): 1339-1345.

    3. Francis BA, et al., Ophthalmology 2011; 118: 1466-1480.


    Dr. Toso is head of the Vitreoretinal Surgery Unit, Department of Ophthalmology, S. Bassiano Hospital, Bassano del Grappa, Italy.

    Dr Antonio Toso

    Dr Antonio Toso is the director of the Vitreo?Retinal Surgery Unit in the Ophthalmic Department of the St Bassiano Hospital in ...

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results